Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
VistaGen Therapeutics ( (VTGN) ) has shared an update.
On November 3, 2025, Vistagen Therapeutics announced the completion of the patient participation phase in the PALISADE-3 Phase 3 clinical trial for fasedienol, aimed at treating social anxiety disorder. This milestone is significant as it brings the company closer to potentially offering the first acute treatment for social anxiety disorder, affecting over 30 million individuals in the U.S. The results from this trial, along with the ongoing PALISADE-4 trial, could support a New Drug Application submission to the FDA, marking a pivotal step in Vistagen’s efforts to address this prevalent mental health condition.
The most recent analyst rating on (VTGN) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on VistaGen Therapeutics stock, see the VTGN Stock Forecast page.
Spark’s Take on VTGN Stock
According to Spark, TipRanks’ AI Analyst, VTGN is a Neutral.
VistaGen Therapeutics shows potential with its clinical advancements and strong cash position, but faces significant financial challenges with ongoing losses and increased R&D expenses. The technical indicators are positive, suggesting a bullish trend, but the negative P/E ratio and lack of dividend yield weigh on the valuation. The company needs to improve operational efficiency and profitability to enhance its overall stock attractiveness.
To see Spark’s full report on VTGN stock, click here.
More about VistaGen Therapeutics
Vistagen Therapeutics, headquartered in South San Francisco, CA, is a late clinical-stage biopharmaceutical company specializing in the development and commercialization of intranasal product candidates called pherines. These products are designed to rapidly activate neurocircuits in the brain through nose-to-brain neurocircuitry, potentially offering safer alternatives to traditional pharmacological treatments. Vistagen focuses on addressing unmet needs in conditions such as social anxiety disorder, major depressive disorder, and vasomotor symptoms associated with menopause.
Average Trading Volume: 570,748
Technical Sentiment Signal: Hold
Current Market Cap: $130.1M
For a thorough assessment of VTGN stock, go to TipRanks’ Stock Analysis page.